Infectious Diseases

Increasing treatment efficacy in children with acute respiratory viral infections

In this study, we evaluated the efficacy and safety of antiviral therapy with inosine pranobex in children and adolescents aged between 3 and 18 years.
Objective. To assess the efficacy and safety of antiviral therapy with inosine pranobex (Groprinosin®) in children and adolescents with acute respiratory viral infections (ARVI) aged between 3 and 18 years.
Patients and methods. In this non-interventional study, we questionnaired physicians from different regions of the Russian Federation. Participation in the study was voluntary. We used continuous screening to form the study cohort. A total of 11,334 children and adolescents of both sexes aged between 3 and 18 years with mild to moderate acute respiratory viral infections (ARVIs) were included into the study. The data were stripped of all personal identifiers. We evaluated the duration of fever and catarrhal manifestations, total disease durations, and frequency of complications and adverse events in the groups compared. Patients in the experimental group received inosine pranobex (Groprinosin), whereas patients in the control group received other therapies.
Results. Children in the experimental group had shorter ARVI duration than controls did: 7.05 ± 2.08 days vs 8.37 ± 2.03 days (р = 0.00001). Moreover, the administration of Groprinosin® significantly decreased the duration of catarrhal symptoms: 4.73 ± 1.41 days in the experimental group vs 5.90 ± 1.51 days in the control group, р = 0.00001. Mean duration of fever in the experimental group was 2.53 ± 0.93 days, whereas patients in the control group had fever during 3.24 ± 0.99 days on average
(р = 0.00001). Children receiving Groprinosin® were 4 times less likely to develop complications. The frequency of adverse events was relatively low in both experimental and control groups (0.4% and 0.76% respectively).
Conclusion. The administration of inosine pranobex (Groprinosin®) in children and adolescents with ARVI significantly reduced the overall duration of the disease as well as duration of fever and catarrhal symptoms. The use of Groprinosin® also ensured a 4-fold reduction in the frequency of ARVI/flu complications. The drug is well tolerated by patients; adverse events were very rare.
Key words: herpes, influenza, inosine pranobex, nasopharyngitis, acute respiratory infection, acute tonsillitis, tonsillopharyngitis. 
For citation: Ruzhentsova T.A., Ploskireva A.A., Aleshina N.I., Astrina O.S., Meshkova N.A., Ivanova I.A., Mogileva A.A. Increasing treatment efficacy in children with acute respiratory viral infections. Infekc. bolezni (Infectious diseases). 2019; 17(2): 46–52. (In Russian).

DOI: 10.20953/1729-9225-2019-2-46-52

Яндекс.Метрика